Relapsing catastrophic antiphospholipid syndrome: Report of three cases

被引:53
作者
Asherson, Ronald A. [1 ]
Espinosa, Gerard [2 ]
Menahem, Solomon [3 ]
Yinh, Janet [4 ]
Bucciarelli, Silvia [2 ]
Bosch, Xavier [2 ]
Cervera, Ricard [2 ]
机构
[1] Univ Witwatersrand, Div Immunol, Sch Pathol, ZA-2196 Johannesburg, South Africa
[2] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Inst Clin Med & Dermatol, Dept Autoimmune Dis, Barcelona, Catalonia, Spain
[3] Alfred Hosp, Dept Renal Med, Melbourne, Vic, Australia
[4] Tufts Univ New England Med Ctr, Boston, MA USA
关键词
relapsing catastrophic antiphospholipid syndrome; catastrophic antiphospholipid syndrome; Asherson's syndrome; antiphospholipid syndrome; antiphospholipid antibodies;
D O I
10.1016/j.semarthrit.2007.08.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The catastrophic variant of the antiphospholipid syndrome (CAPS), also now known as Asherson's syndrome, is defined as a potential life-threatening variant of the antiphospholipid syndrome, which is characterized by multiple small-vessel thrombosis that can lead to multiorgan failure. Relapses in patients with the CAPS are very uncommon. Objective: To describe the clinical and laboratory features of patients with relapsing episodes of CAPS. Methods: Three patients with relapsing CAPS are presented with their clinical and laboratory features. Results: Seven episodes of CAPS that occurred in the 3 patients reported were analyzed. The median time between the episodes of CAPS was 12.5 months (range, 2.5-48). Precipitating factors were identified in 2 episodes only (Legionella respiratory tract infection and periodontal infection). The most significant manifestations of the episodes were renal involvement (5 episodes), central nervous system and cardiac involvement (4 episodes), and pulmonary and hepatic involvement (3 episodes each). Interestingly, laboratory features of definite microangiopathic hemolytic anemia (MHA) were present in 5 of 7 episodes of relapsing CAPS. The remaining episodes presented with thrombocytopenia, schistocytes, and anemia but data concerning hemolysis and Coombs tests were not reported. Rituximab was used in 2 episodes. Conclusions: Relapses occur very infrequently in patients with the CAPS. The presence of MHA is common in these patients, suggesting that an association between MHA and relapses of CAPS could be present and that a "continuum" between various MHAs might exist, as recently suggested. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 27 条
[1]  
Asherson R.A., 2006, FUTURE RHEUMATOL, V1, P355, DOI [10.2217/17460816.1.3.355, DOI 10.2217/17460816.1.3.355]
[2]   Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome:: clinical and haematological characteristics of 23 patients [J].
Asherson, RA ;
Espinosa, G ;
Cervera, R ;
Gómez-Puerta, JA ;
Musuruana, J ;
Bucciarelli, S ;
Ramos-Casal, M ;
Martínez-González, AL ;
Ingelmo, M ;
Reverter, JC ;
Font, J ;
Triplett, DA .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :943-946
[3]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[4]   Catastrophic antiphospholipid syndrome - Proposed guidelines for diagnosis and treatment [J].
Asherson, RA ;
Espinosa, G ;
Cervera, R ;
Font, J ;
Reverter, JC .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2002, 8 (03) :157-165
[5]  
ASHERSON RA, 1992, J RHEUMATOL, V19, P508
[6]   Catastrophic antiphospholipid syndrome -: Clues to the pathogenesis from a series of 80 patients [J].
Asherson, RA ;
Cervera, R ;
Piette, JC ;
Shoenfeld, Y ;
Espinosa, G ;
Petri, MA ;
Lim, E ;
Lau, TC ;
Gurjal, A ;
Jedryka-Góral, A ;
Chwalinska-Sadowska, H ;
Dibner, RJ ;
Rojas-Rodriguez, J ;
Garcia-Carrasco, M ;
Grandone, JT ;
Parke, AL ;
Barbosa, P ;
Vasconcelos, C ;
Ramos-Casals, M ;
Font, J ;
Ingelmo, M .
MEDICINE, 2001, 80 (06) :355-377
[7]   New subsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic antiphospholipid syndromes ("MAPS") [J].
Asherson, Ronald A. .
AUTOIMMUNITY REVIEWS, 2006, 6 (02) :76-80
[8]  
Bayraktar UD, 2007, J RHEUMATOL, V34, P346
[9]   The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome:: analysis of a series of 47 patients [J].
Bucciarelli, S ;
Espinosa, G ;
Asherson, RA ;
Cervera, R ;
Claver, G ;
Gómez-Puerta, JA ;
Ramos-Casals, M ;
Ingelmo, M ;
Font, J .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (01) :81-86
[10]   Mortality in the catastrophic antiphospholipid syndrome - Causes of death and prognostic factors in a series of 250 patients [J].
Bucciarelli, Silvia ;
Espinosa, Gerard ;
Cervera, Ricard ;
Erkan, Doruk ;
Gomez-Puerta, Jose A. ;
Ramos-Casals, Manuel ;
Font, Josep ;
Asherson, Ronald A. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2568-2576